LabTech(SH:688056) Xin Lang Cai Jing·2025-10-31 06:35Core Viewpoint - 莱伯泰科 is a leading company in the domestic experimental analysis instrument sector, focusing on R&D, production, and sales, with a full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, 莱伯泰科 achieved revenue of 285 million yuan, ranking 35th among 61 peers, with the industry leader 川仪股份 generating 4.89 billion yuan [2] - The net profit for the same period was 32.55 million yuan, also ranking 35th, while the top performer 川仪股份 reported a net profit of 469 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, 莱伯泰科's debt-to-asset ratio was 11.55%, lower than the industry average of 27.43%, indicating strong solvency [3] - The gross profit margin was 45.80%, higher than the industry average of 43.50%, reflecting robust profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.49% to 3,181, while the average number of shares held per shareholder increased by 14.27% to 21,200 shares [5] - The eighth largest shareholder, 大成睿享混合 A, reduced its holdings by 114,200 shares [5] Group 4: Management Compensation - The chairman and general manager, 胡克, received a salary of 2.5117 million yuan in 2024, an increase of 111,000 yuan from 2023 [4] Group 5: Analyst Predictions - 光大证券 revised down the net profit forecast for 2025 and 2026 to 50 million and 58 million yuan, respectively, while introducing a new forecast for 2027 at 67 million yuan [5] - 国泰海通证券 maintained net profit forecasts for 2025, 2026, and 2027 at 57 million, 80 million, and 94 million yuan, respectively, and raised the target price to 44.10 yuan [6]